Payment overview · 2025
General Payments
$1,732.04
80 reported records · 20 companies
Healthcare provider profile · identity verified
James I Klepper, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · HUNTINGTON, NY · NPI 1043303233
Verified facts
What the public records show
CMS Open Payments records show James I Klepper, M.D. received $1,732.04 in general payments during 2025 across 80 reported records.
Novartis Pharmaceuticals Corporation accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Entresto, Farxiga, Jardiance, Ozempic, Synthroid, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Edarbyclor by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Nexlizet by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $267.83 | 15.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $207.83 | 12.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $203.52 | 11.8% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $176.66 | 10.2% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.83 | 9.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.09 | 5.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.43 | 4.8% | 4 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.05 | 4.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.14 | 4.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.74 | 3.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $50.39 | 2.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.18 | 2.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.24 | 2.5% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $37.76 | 2.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.99 | 1.7% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $28.23 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.19 | 1.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.92 | 1.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $25.75 | 1.5% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $14.27 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,713.19 | 79 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $267.83 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $207.83 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $160.73 | 7 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $109.59 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.65 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $82.43 | 4 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $76.05 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.14 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $70.73 | 4 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $68.18 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.74 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.19 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 361 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 48 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 99 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 17 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
361 | 91 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
361 | 91 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1447 | 404 |
| Atorvastatin Calcium | Atorvastatin Calcium | 571 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 147 |
| Metoprolol Succinate | Metoprolol Succinate | 496 | 137 |
| Ezetimibe | Ezetimibe | 467 | 140 |
| Mounjaro | Tirzepatide | 427 | 67 |
| Alprazolam | Alprazolam | 373 | 111 |
| Eliquis | Apixaban | 361 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 95 |
| Zolpidem Tartrate | Zolpidem Tartrate | 321 | 62 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 260 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 221 | 68 |
| Omeprazole | Omeprazole | 218 | 76 |
| Simvastatin | Simvastatin | 198 | 56 |
| Metformin Hcl | Metformin Hcl | 178 | 53 |
| Carvedilol | Carvedilol | 171 | 49 |
| Vascepa | Icosapent Ethyl | 169 | 35 |
| Repatha Sureclick | Evolocumab | 165 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 42 |
| Jardiance | Empagliflozin | 133 | 26 |
| Valsartan | Valsartan | 126 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 39 |
| Furosemide | Furosemide | 119 | 40 |
| Losartan Potassium | Losartan Potassium | 104 | 34 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 101 | 28 |
| Xarelto | Rivaroxaban | 100 | 25 |
| Synthroid | Levothyroxine Sodium | 99 | 27 |
| Lisinopril | Lisinopril | 96 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 96 | 28 |
| Allopurinol | Allopurinol | 95 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 29 |
| Sertraline Hcl | Sertraline Hcl | 82 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 22 |
| Wegovy | Semaglutide | 81 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 26 |
| Montelukast Sodium | Montelukast Sodium | 78 | 21 |
| Ozempic | Semaglutide | 77 | 17 |
| Gabapentin | Gabapentin | 76 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 28 |
| Potassium Chloride | Potassium Chloride | 76 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 21 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 68 | 17 |
| Atenolol | Atenolol | 64 | 16 |
| Finasteride | Finasteride | 62 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 18 |
| Prednisone | Prednisone | 56 | 31 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 54 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Entresto | Sacubitril/Valsartan | 48 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 17 |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | 11 |
| Azithromycin | Azithromycin | 42 | 32 |
| Edarbi | Azilsartan Medoxomil | 40 | suppressed |
| Eszopiclone | Eszopiclone | 40 | suppressed |
| Praluent Pen | Alirocumab | 40 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 39 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 36 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | suppressed |
| Famotidine | Famotidine | 32 | 15 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | 15 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 16 |
| Diazepam | Diazepam | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 11 |
| Niacin Er | Niacin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,732.04 · 80 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AIRSUPRA, AREXVY, CAMZYOS, CAPVAXIVE, COMIRNATY, EDARBI, ELIQUIS, ENTRESTO, FARXIGA, FFRct, FUROSCIX, Flector, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, Licart, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, SHINGRIX, SYNTHROID, Tirosint, UBRELVY, VERQUVO, VYNDAQEL, WAINUA, WATCHMAN FLX, Wegovy, t:slim X2 Insulin Pump with Control-IQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error